Physician profile
Selman Manuel
NPI 1992170427
$1,251.39
in general payments reported to CMS, 2019-2025
11 companies · $786 in 2025
The $786 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $98.87 · 2024: $367 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $380.93 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $229.45 | 2024 | Spravato |
| Abbvie INC. | $195.61 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $179.13 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $64.26 | 2024 | |
| Indivior INC. | $55.50 | 2023 | Perseris |
| Bioxcel Therapeutics, INC. | $43.37 | 2023 | Igalmi |
| Vanda Pharmaceuticals INC. | $31.67 | 2025 | Fanapt |
| Alkermes, INC. | $24.18 | 2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $24.07 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.22 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selman Manuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.